November 2026, Vol 16, No 6
This article walks through the separate clocks that decide when a new clinician or site can be billed and closes with a shareable readiness checklist. Read More ›
Non-muscle–invasive bladder cancer (NMIBC) treatment is undergoing a transformative shift fueled by cutting-edge therapies, novel strategies, and refined approaches to patient care. Let’s explore the pivotal breakthroughs driving progress in NMIBC care. Read More ›
Breast cancer care is advancing quickly across
early-stage and metastatic disease. New data are extending time on therapy, refining treatment sequencing, and reducing treatment burden. Here are 4 key studies shaping care right now. Read More ›
On September 4, 2026, the FDA granted accelerated approval to camizestrant (ETCAMAH) in combination with a CDK4/6 inhibitor for adults with HR-positive, HER2-negative metastatic or locally advanced breast cancer who develop an ESR1 mutation while receiving first-line aromatase inhibitor (AI) therapy. Read More ›
Think about how dramatically patient communication has changed. Not that long ago, most communication happened by telephone, mail, or face-to-face. Today, patients may receive texts, portal messages, automated reminders, electronic forms, and other digital communications, sometimes all from the same practice. Read More ›
The Inflation Reduction Act (IRA) of 2022 included several provisions intended to lower the costs of prescription drug prices for patients while also lowering prescription drug spending under the federal Medicare program. Read More ›
It is well known that cancer management presents numerous challenges, challenges that crop up from the beginning of care—at diagnosis. Read More ›